Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Matthew Nazzaro
Observed name:
Matthew J Nazzaro
Institutions:
Nationwide Children's Hospital,
The Ohio State University
Observed institutions:
Nationwide Children's Hospital,
Dana-Farber Cancer Institute,
Abigail Wexner Research Institute,
The Ohio State University
ORCID:
0000-0003-1049-086X
Observed ORCID:
0000-0003-1049-086X
OpenAlex ID:
A5003926896
Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma
2023
·
Sakthi Rajendran
, Yang Hu
, et al.
·
Cell Reports
·
73
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
2021
·
Livius Penter
, Yi Zhang
, et al.
·
Blood
·
47
PDF
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
2021
·
Leonie K de Klerk
, Anuj K Patel
, et al.
·
Journal for ImmunoTherapy of Cancer
·
33
PDF
High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples
2020
·
Emily M. Thrash
, Katja Kleinsteuber
, et al.
·
STAR Protocols
·
30
PDF
Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment
2023
·
Alessandro Canella
, Matthew Nazzaro
, et al.
·
Cell Reports
·
26
PDF
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
2021
·
Patrick A Ott
, Matthew Nazzaro
, et al.
·
Journal for ImmunoTherapy of Cancer
·
18
PDF
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
2021
·
Reid W. Merryman
, Robert Redd
, et al.
·
Transplantation and Cellular Therapy
·
18
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
2024
·
Jiajia Chen
, Giuseppe Tarantino
, et al.
·
OncoImmunology
·
13
BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics in vivo
2024
·
Alessandro Canella
, Matthew Nazzaro
, et al.
·
Molecular Therapy Oncology
·
9
Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials
2022
·
Charlotte Abrecht
, Margaret Hallisey
, et al.
·
STAR Protocols
·
7
PDF
DIPG-16. Evaluation of myeloid component of DIPG microenvironment
2022
·
Deepak Mishra
, Sakthi Rajendran
, et al.
·
Neuro-Oncology
·
3
In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages
2026
·
Matthew Nazzaro
, Elaine R. Mardis
, et al.
·
OncoImmunology
·
2
PDF
Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
2026
·
Matthew Nazzaro
, Elaine R. Mardis
, et al.
·
Molecular Therapy Oncology
·
1
TMIC-50. Targeting MHCII invariant chain transmembrane protein CD74 confers a survival advantage in a preclinical model of glioma malignant progression
2025
·
Mark Damante
, Alessandro Canella
, et al.
·
Neuro-Oncology
PDF
Abstract 642: Peripheral immune cells associated with toxicity to ipilimumab plus nivolumab checkpoint blockade in patients with metastatic melanoma
2025
·
Jiajia Chen
, Joanna Baginska
, et al.
·
Cancer Research
895 Immunomodulatory role of CD74 in low-grade glioma bone marrow-derived myeloid cells
2024
·
Alessandro Canella
, Sakthi Rajendran
, et al.
·
Journal for ImmunoTherapy of Cancer
709 Chemotherapy agent trabectedin demonstrates immunomodulatory properties that improve efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
2024
·
Matthew Nazzaro
, Alessandro Canella
, et al.
·
Journal for ImmunoTherapy of Cancer
Immu-15. Cd74/mif Signaling Axis Disruption in Bone Marrow-derived Myeloid Cells Delays Malignant Progression in a Preclinical Model of Glioma
2024
·
Alessandro Canella
, Sakthi Rajendran
, et al.
·
Neuro-Oncology
PDF
Trabectedin modulates the glioma innate and adaptive immune microenvironment in vivo
2024
·
Matthew Nazzaro
, Prajwal Rajappa
, et al.
·
The Journal of Immunology
Abstract 6397: Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma
2024
·
Joanna Baginska
, Jiajia Chen
, et al.
·
Cancer Research
Tmic-59. Il-2 Secreting Engineered Myeloid Cells Potentiate Cytotoxic Effector Cell Activation to Delay Malignant Progression in a Preclinical Model of Glioma
2023
·
Alessandro Canella
, Matthew Nazzaro
, et al.
·
Neuro-Oncology
PDF
406 Reprogramming the glioma immunosuppressive tumor microenvironment with engineered myeloid cells that release IL-2 to delay malignant progression
2023
·
Alessandro Canella
, Matthew Nazzaro
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Exth-97. Bone Marrow-derived Engineered Myeloid Cells Enhance the Trafficking and Activation of Cytotoxic T Cells in the Glioma Microenvironment
2022
·
Alessandro Canella
, Matthew Nazzaro
, et al.
·
Neuro-Oncology
PDF
Show more works
View as search
Works count:
23
Citation count:
280
H-index:
9
I10-index:
8
Year
Topic
Type